Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Posts Earnings Results, Beats Expectations By $0.18 EPS

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) released its quarterly earnings data on Monday. The company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.18 by $0.18, Zacks reports. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 13.56% and a net margin of 41.08%.The company had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $970.69 million.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

OTCMKTS:SGIOY opened at $9.43 on Tuesday. Shionogi & Co., Ltd. Unsponsored ADR has a 12-month low of $7.65 and a 12-month high of $12.00. The firm has a market capitalization of $16.05 billion, a price-to-earnings ratio of 11.79, a P/E/G ratio of 3.55 and a beta of 0.08. The stock’s 50 day moving average price is $8.83 and its two-hundred day moving average price is $9.88. The company has a quick ratio of 1.46, a current ratio of 1.58 and a debt-to-equity ratio of 0.01.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Monday, June 15th. Jefferies Financial Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Finally, Zacks Research raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research report on Monday, May 25th. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Shionogi & Co., Ltd. Unsponsored ADR currently has a consensus rating of “Buy”.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.